Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down – Here’s Why

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s share price gapped down before the market opened on Monday . The stock had previously closed at $22.2775, but opened at $21.11. Hikma Pharmaceuticals shares last traded at $21.10, with a volume of 22,673 shares changing hands.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Citigroup reissued a “buy” rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, August 12th. Barclays upgraded shares of Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Moderate Buy”.

Hikma Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.82 and a quick ratio of 1.06. The business has a 50 day moving average price of $21.80 and a two-hundred day moving average price of $19.72.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad portfolio of medicines. Its products include generic and specialty pharmaceuticals, injectable medicines, and branded treatments across a range of therapeutic areas.

The company operates through three principal businesses: Injectables, which supplies hospital and clinical medicines; Generics, which offers off-patent prescription products, primarily in the United States; and Branded, which markets medicines under established brand names across the Middle East and North Africa.